Increased use of rapid diagnostic techniques such as PCR may allow prompt discontinuation of vancomycin when not indicated. Further development of alternative antimicrobials may also lessen its use. If novel biomarkers and anti-oxidants provide improved monitoring or some protection against renal injury, more aggressive dosing might be more accepted. Clarification of differences between generic sources of the drug may also clarify potency and safety issues. Despite a mere 2 years since the vancomycin guidelines were first published, further data has questioned some of our long-held tenets of efficacy, toxicity and monitoring and directed areas for future research to optimize vancomycin usage while identifying risk factors for toxicity.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Expert Rev Anti Infect Ther. 2011;9(6):657-667. © 2011 Expert Reviews Ltd.
Cite this: Vancomycin Dosing and Monitoring 2 Years After the Guidelines - Medscape - Jun 01, 2011.